NCT06652165View on ClinicalTrials.gov

Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2028

Conditions
DLBCL
Interventions
DRUG

zanubrutinib combined with BEAM

zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2

DRUG

BEAM

camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2

All Listed Sponsors
lead

Ruijin Hospital

OTHER